Point Therapeutics, Inc. (NASDAQ: POTP) 34% LOWER; Provided a clinical update on its current clinical program which includes two Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE